Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed,
and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government
operating status and resumption of normal operations can be found at opm.gov.
Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease (ALPO)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
55 Years to 90 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Informed consent obtained from the patient and legally acceptable representative, if required
Informed consent obtained from the caregiver
Males and and females between 55-90 years
Diagnosis of probable Alzheimer's disease, history of progressive cognitive deterioration
Brain imaging consistent with Alzheimer's disease
Mini-mental state examination score 12-21
Treated with donepezil, rivastigmine or galantamine
At least mild level of behavioral symptoms
Other types of dementias
Modified Hachinski Ischemia Score > 4
Use of memantine, antipsychotics, anticholinergic medication and benzodiazepines (at a max of 3 nights/week) within 2 months
Changes in antidepressant dosing within 2 months
Use of other psychotropic agents
Myocardial infarction within the past 2 years
Malignancy within the past 5 years
Suicidal ideation, risk of suicide
History of alcoholism or drug abuse within 5 years
Clinically significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, neurological or psychiatric disorder or any other major concurrent illness